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study the cumulative incidence of pharmacological treat-
ment regimens, beneﬁts utilization, and cost differences
between the treatment and non-treatment groups.
METHODS: Examining a database of 78,655 employees
with complete medical and prescription drug data for a
four-year period, this study includes the 1,944 employees
who had clinical diagnoses of OAB (ICD9 codes 595, 
596 and 788). Treatment incidence and health beneﬁts
utilization is reported for this population.
RESULTS: 15.7% of the employee population examined
were actively seeking pharmaceutical treatment for OAB.
Employees seeking treatment were more likely to be older
(p < .001), female (p < .01), and non-union (*p < .07).
Employees with a dependent diagnosed with OAB
incurred ($1,170) in additional annual beneﬁts cost after
controlling for demographic and OAB severity variables
(p < .02). Employees diagnosed with OAB used 62%
fewer co-morbid medical services (74% less cost) after
initial treatment. After controlling for other factors,
employees in the treatment group were found to have
lower annual STD beneﬁts cost ($554) (p < .04) and lower
total annual costs ($248) (*p < .82).
CONCLUSIONS: One in every six OAB-diagnosed
employees examined actively sought pharmaceutical
treatment. Employees who are care-givers for dependents
with OAB use signiﬁcantly more health-related beneﬁts
on an annual basis than employees without such respon-
sibilities. Post-treatment employees experience a reduc-
tion in the use of co-morbid medical services and
OAB-related medical services. OAB treatment may rep-
resent a “ripple-effect” beneﬁt to employers by reducing
total beneﬁts cost. Further research about OAB treat-
ment beneﬁts for employers and employees over time is
appropriate.
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End-stage renal disease (ESRD) patients referred to a
nephrologist at least 4 months before initiation of renal
replacement therapy (RRT) (“early referral”; ER) were
found to have better survival than those referred at a later
stage (“late referral”; LR). However, ER may result in
earlier utilization of medical resources, which is a greater
ﬁnancial burden on Medicare.
OBJECTIVES: To examine the budget impact of ER for
elderly Medicare ESRD beneﬁciaries.
METHODS: The decision model considered Medicare
beneﬁciaries aged 65 and above in their ﬁrst year of
ESRD. The preliminary model included an incident
cohort at 6 months prior to RRT initiation and followed
them for one year. It was expanded to a Markov model
for longer timeframes with a 3% discount rate. ER and
LR differed by three parameters: survival advantage asso-
ciated with early initiation of dialysis; higher likelihood
of selecting peritoneal dialysis for ER; and higher costs of
initial dialysis for LR. Base case values were obtained
from the literature. RRT modalities included center
hemodialysis (HD), home HD, CAPD/CCPD, other 
dialysis, and transplantations. Transition probabilities,
survival, and costs associated with each modality were
obtained from the United State Renal Data System 
aggregate data.
RESULTS: For the base case scenario, ER was cost-saving
for Medicare, especially for ﬁrst-year ESRD beneﬁciaries.
One-year analysis suggested a 10% increase in ER would
reduce the Medicare budget by $2,541 per ESRD beneﬁ-
ciary. The reduction became $2,159 and $1,801 over 3-
and 5-year periods, respectively, as the survival advantage
of ER translated into longer maintenance dialysis dura-
tions. A larger reduction could be realized if more bene-
ﬁciaries were referred earlier. Sensitivity analysis indicated
the ﬁndings of budget reduction were robust.
CONCLUSIONS: Early referral to nephrologists may
reduce Medicare’s budget.
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OBJECTIVES: The Symptom Frequency and Bother-
someness (SFB) scale measures the frequency and bother-
someness of patient symptoms associated with urge
urinary incontinence, mixed stress and urge urinary
incontinence, and painful irritable bladder syndromes.
The SFB has demonstrated good psychometric perfor-
mance in mixed urinary incontinence. The objective of
this study was to modify the original SFB instrument to
measure symptom frequency and bothersomeness for
stress urinary incontinence symptoms (SUI).
METHODS: The SFB was revised to address symptoms
speciﬁc to SUI based on a review of current literature,
data from a previous pilot study, and consultation with a
urologist. The Revised Version of the instrument (SFB-
SUI) was piloted with eight patients diagnosed with pure
SUI. Cognitive Debrieﬁng was conduced to (1) assess the
relevance and importance of the items to patients with
SUI; (2) identify issues in formatting, language, or clarity;
(3) assess construct validity; and (4) identify gaps in key
content areas.
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RESULTS: All eight patients favorably appraised the
format of the revised instrument. Patients reported that
the SFB-SUI generally provided an accurate assessment of
their condition and associated bothersomeness. Changes
resulting from the interviews included the addition of one
new item, the deletion of two items, and modiﬁcation of
both response scales. The ﬁnal version of the SFB-SUI
now consists of 8 items.
CONCLUSION: Preliminary investigation of the SFB-SUI
indicates that it is a two-subscale measure for symptom
frequency and bothersomeness speciﬁc to stress urinary
incontinence. Psychometric evaluation will be performed
in subsequent clinical trials being conducted in stress
urinary incontinence patients.
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OBJECTIVES: Overactive bladder (OAB) is characterized
by bothersome symptoms of urinary frequency and
urgency that occur with or without urge incontinence,
and it has been shown to have signiﬁcant impact on
health-related quality of life (HRQL). Since OAB is
deﬁned by symptoms, the evaluation of treatment 
effectiveness should be based upon patient perception.
The purpose of this study was to assess the validity and
responsiveness of a global patient-report measure—the
Perception of Bladder Condition (PBC) in Overactive
Bladder.
METHODS: OAB patients were treated with Tolterodine
Extended Release 4mg/day for 12 weeks. Patient evalua-
tions, which included the PBC, OAB-q (measure of
symptom bother and HRQL), and micturition variables
(3-day diaries: frequency, incontinence, urgency), were
conducted at baseline, 4 weeks, and 12 weeks. The PBC
is a single item that assesses current urinary problems on
a 6-point scale. PBC scores were evaluated with other
measures of treatment efﬁcacy using t-tests and ANOVAs
for all assessment periods.
RESULTS: 865 patients completed the study (mean age =
61 years; 73% female; 89% Caucasian). Higher severity
PBC responses were signiﬁcantly associated with greater
symptom bother and lower HRQL at each assessment
period (p < 0.05). Associations between PBC and mic-
turition variables followed similar patterns. Compared
with patients who did not report improvement on the
PBC, patients who improved demonstrated signiﬁcantly
greater improvement from baseline to week 12 on all
OAB-q scales (p < 0.0001), micturition frequency (p <
0.0001), incontinence episodes (p < 0.002), and urgency
episodes (p < 0.005). Patients reporting major improve-
ment on the PBC (>2 response options) consistently
demonstrated signiﬁcantly greater improvement on other
efﬁcacy measures compared to patients reporting minor
improvement.
CONCLUSIONS: The Perception of Bladder Condition
demonstrated good construct validity and responsiveness
among patients receiving Tolterodine Extended Release 
4mg/day for Overactive Bladder. It appears to be a useful
tool for evaluating patients’ global impressions of bladder
condition in clinical trials of OAB treatments.
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OBJECTIVES: Urinary urgency is a central symptom of
overactive bladder (OAB) and is particularly bothersome
due to its unpredictable nature and consequent impact 
on daily living. There are no objective clinical measures
of urgency and there is a need for a validated, standard-
ized instrument. The purpose of this study was to 
ascertain the validity and responsiveness of the Urgency
Perception Scale (UPS) as an indicator of perceived
urinary urgency.
METHODS: Content validity was assessed by interviews
with OAB patients and clinical experts. Secondary 
analyses of clinical and patient outcome data gathered
from three separate clinical studies of tolterodine
extended release were performed to evaluate the psycho-
metric properties of the UPS. Construct validity was
assessed by correlations between the UPS and micturition
diaries and other patient-reported outcomes including
perception of bladder condition, perception of treatment
beneﬁt, SF-36, King’s Health Questionnaire, Overactive
Bladder Questionnaire, and Overall Treatment Effect
scale. Analysis of variance was used to assess the UPS’s 
construct validity and responsiveness.
RESULTS: The UPS was considered an appropriate and
reasonable assessment of urinary urgency by patients 
(n = 16) and clinicians (n = 7). Data from a total of 2,686
patients from three clinical studies were analyzed; the
baseline clinical and demographic characteristics were
similar among the three patient samples. Correlations
with patient outcomes and clinical variables were small
to moderate (0.09 to 0.46, p < 0.01) with higher corre-
lations associated with disease-speciﬁc patient outcome
measures. Responsiveness was supported by improve-
ments in the UPS score at the end of treatment that were
consistently associated with signiﬁcant (p < 0.05) reduc-
tions in micturitions associated with urgency, inconti-
nence episodes, and pad use.
CONCLUSION: The UPS is a conceptually valid scale
with evidence of construct validity and responsiveness
from three clinical studies. This work demonstrates that
perceived urinary urgency and changes in urinary urgency
can be assessed.
